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ABSTRACT The aim of this review was to identify the effectiveness of therapies added on to conventional
exercise training to maximise exercise capacity in patients with chronic obstructive pulmonary disease (COPD).
Electronic databases were searched, identifying trials comparing exercise training with exercise training
plus “add-on” therapy. Outcomes included peak oxygen uptake (V′O2peak), work rate and incremental/
endurance cycle and field walking tests. Individual trial effects on exercise capacity were extracted and
collated into eight subgroups and pooled for meta-analysis. Sensitivity analyses were conducted to explore
the stability of effect estimates across studies employing patient-centred designs and those deemed to be of
“high” quality (PEDro score >5 out of 10).
74 studies (2506 subjects) met review inclusion criteria. Interventions spanned a broad scope of clinical
practice and were most commonly evaluated via the 6-min walking distance and V′O2peak. Meta-analysis
revealed few clinically relevant and statistically significant benefits of “add-on” therapies on exercise
performance compared with exercise training. Benefits favouring “add-on” therapies were observed across
six different interventions (additional exercise training, noninvasive ventilation, bronchodilator therapy,
growth hormone, vitamin D and nutritional supplementation). The sensitivity analyses included
considerably fewer studies, but revealed minimal differences to the primary analysis.
The lack of systematic benefits of “add-on” interventions is a probable reflection of methodological
limitations, such as “one size fits all” eligibility criteria, that are inherent in many of the included studies
of “add-on” therapies. Future clarification regarding the exact value of such therapies may only arise from
adequately powered, multicentre clinical trials of tailored interventions for carefully selected COPD patient
subgroups defined according to distinct clinical phenotypes.
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Introduction
Pulmonary rehabilitation is a highly effective treatment for individuals with chronic obstructive pulmonary
disease (COPD), and is associated with significant improvement in quality of life, healthcare utilisation
and exercise capacity [1–3]. Benefits of exercise training include improvements in oxygen uptake and
endurance time [4], reduced symptoms [1] and muscle composition adaptations such as increased
capillary/fibre ratio [5] and increased oxidative capacity [6]. In recent years, significant attention has been
directed towards improving the already beneficial effects of pulmonary rehabilitation via application of
additional (“add-on”) therapies on top of conventional exercise training. This is probably due to the
emergence of newer therapies (such as pharmacological medicines), new exercise modalities and more
readily available equipment (such as portable noninvasive ventilation (NIV) units). The effectiveness of
such supplemental therapies, however, is unclear.
The only existing systematic review of such therapies was conducted over a decade ago [7]. Due to
significant methodological limitations and small study sample sizes, the authors concluded there was
insufficient evidence to estimate the value of most supplemental interventions except supplemental oxygen
(which demonstrated a clear lack of benefit). The increased number of studies conducted since this review,
however, offers greater potential to better estimate the usefulness of “add-on” therapy to exercise training. It
is also crucial that the effects of interventions seeking to boost training responses are rigorously determined
according to a robust range of end-points specific to the physiological adaptations of exercise in this patient
group. This is likely to improve our understanding of the mechanisms explaining their role in exercise
training, and potentially enhance their translation into clinical practice. If no further clarification is able to
be determined regarding the value of “add-on” therapies to exercise training in patients with COPD, one
must question the scientific approach to clinical research in this area and consider how best to address any
emergent shortcomings in order to improve future studies and, ultimately, clinical patient care.
The principal aim of this review was to determine whether “add-on” therapies, applied in conjunction
with conventional exercise training in pulmonary rehabilitation, improve exercise capacity in individuals
with COPD more than conventional exercise training alone. The secondary aim was to examine the
effectiveness of “add-on” therapies specifically in studies that adopted highly specific, patient-centred
approaches to the study design. As pulmonary rehabilitation benefits are driven largely by physiological
adaptation of skeletal muscles in response to exercise training, we focused on a comprehensive range of
outcomes specifically related to exercise capacity.
Methods
Study selection criteria
Randomised and quasi-randomised controlled clinical trials were eligible for inclusion if they compared
exercise training (comprising aerobic (lower limb endurance) training) with exercise training plus at least
one additional treatment modality (no exclusions) in patients with COPD (defined by study authors).
Studies were considered quasi randomised if participants were assigned to interventions by methods such as
sequential allocation, date of birth, etc. In line with the clear physiological mechanisms underpinning
exercise training effects in COPD, studies were only included in the review if they reported data from at
least one of the following exercise capacity outcomes: peak oxygen uptake (V′O2peak; metabolic equivalents),
peak work rate (watts), cycle endurance test (time), incremental shuttle walk test (ISWT; distance, time),
endurance shuttle walk test (ESWT; time, distance), 6-min walk test (6MWT; distance) and 12-min walk
test (12MWT; distance). Outcomes such as quality of life or symptoms were not considered for this review.
Search strategy
Six databases (CENTRAL, MEDLINE, EMBASE, SciELO, PEDro and CINAHL) were searched in April
2014 without limits using the following subject headings (no free text terms): (COPD OR chronic
obstructive pulmonary disease) AND (randomised OR randomized) AND (exercis* OR exercise training
OR aerobic exercise training). Differences between database subject heading structures (e.g. MeSH versus
Emtree) resulted in differences between some search terms across platforms. No hand searching of
conference proceedings was undertaken. Search yields were exported to Reference Manager v12 (Thomson
Reuters, Philadelphia, PA, USA) and duplicates discarded. Studies were scrutinised on title and abstract by
two independent reviewers (C.A. Camillo and H. van Remoortel) and coded as either “include”, “exclude”
or “awaiting full text”. Disagreements were resolved by an independent, third reviewer (C.R. Osadnik).
Eligibility criteria were applied by two study investigators and further hand searching performed by
examination of reference lists of included studies and comparison with the earlier systematic review [7].
Studies that included more than one relevant “add-on” therapy type (e.g. pulmonary rehabilitation versus
pulmonary rehabilitation plus oxygen versus pulmonary rehabilitation plus nutrition) were included but
represented once in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
flow diagram.
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Data extraction and quality appraisal
Data were extracted into an electronic spreadsheet using a standardised template. Study quality was
assessed using the PEDro scale. This validated scale [8] rates internal and external validity according to 11
criteria, appraised according to standardised decision rules, to derive a total quality score out of 10
(higher=better; first item not quantified). No studies were excluded on the basis of quality. Where data
were missing or unclear, attempts were made to contact authors via email. Study characteristics and
quality were summarised and presented in tables.
Analysis
Data were pooled for meta-analysis in Review Manager v5.3.5 (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark) according to eight clinically homogenous intervention groups.
These were: 1) additional exercise training modalities, with subgroups for lower limb strength training,
upper and lower limb strength training and other; 2) NIV; 3) oxygen; 4) heliox; 5) prescription
medications, with subgroups for tiotropium, anabolic steroids, growth hormone, vitamin D and hypertonic
saline; 6) nutrition, with subcategories for proteins/fats, creatine and amino acids; 7) breathing exercises,
with subgroups of inspiratory muscle training and breathing retraining; and 8) other. A complete list of
interventions included within each group classification is provided in table 1. Data were entered as change
from baseline values wherever possible. If change data were unable to be obtained (from the article or
author contact), end-point (post-intervention) data were included in the meta-analysis in accordance with
Cochrane guidelines [83].
Data were combined on an outcome-by-outcome basis using weighted mean differences of native metrics
(e.g. metres, L·min−1, etc.) with a fixed effect model wherever possible. Standardised mean differences were
used to pool data for outcomes containing multiple measurement types (e.g. walk test time and distance).
A random effects model was used where statistical heterogeneity was “greater than moderate”, indicated by
an I2 statistic >60% and Chi-squared p<0.05. For studies that involved multiple “add-on” interventions,
participant numbers in the control group were evenly divided for analysis according to the number of
interventions, in order to derive accurate effect estimates and avoid data duplicity [83]. Data were not
weighted or pooled across different intervention groups due to clinical heterogeneity regarding their
application. Data were summarised in a meta-analysis matrix, with each cell representing the result of the
pooled analysis result for a given intervention (row) on a given outcome (column). Data from individual
studies may therefore appear more than once across columns. A representative forest plot was generated
for the most commonly reported outcome (6MWT). The secondary aim of the study was addressed via
meta-analysis of data originating only from studies that used highly specific eligibility criteria deemed well
suited to the “add-on” intervention, in accordance with a patient-centred care model.
Sensitivity analyses
One sensitivity analysis was defined a priori and performed to determine the impact of studies identified
as quasi randomised on effect estimates. A post hoc analysis was also undertaken to explore the impact of
removing studies deemed to be low quality (PEDro score ⩽5) from the principal analysis. For both
analyses, relevant studies were removed from the principal meta-analysis and findings compared between
the original and subsequent analyses.
Results
From 2524 records identified in the database search, 74 studies of 2506 individuals with COPD met
eligibility criteria and were included in the review (figure 1). Characteristics of the included studies are
presented in table 1 and figure 2.
Three studies [24, 33, 81] reported data from more than one appropriate intervention arm. The
methodological quality of the included studies was moderate (median (interquartile range) PEDro score 5
(4–7); table 2), due mainly to lack of intention-to-treat analysis (n=63), therapist blinding (n=55) and
allocation concealment (n=54). Significant statistical heterogeneity was only observed in five weighted
analyses, namely: nutritional supplementation (V′O2peak I2=63%), anabolic steroids supplementation
(V′O2peak I2=66%), NIV (cycled endurance time I2=74%), breathing retraining (12MWT I2=74%) and growth
hormone (6MWT I2=82%). Inspection of study methodology and participant characteristics of these trials
revealed minor differences that were not considered indications for exclusion from analysis. Meta-analysis of
these data therefore proceeded with application of a random effects model (table 3). The duration of
interventions varied largely, ranging from 10 to 50 sessions (mean±SD 27±19 sessions) and exceptionally
reaching 108 sessions (breathing exercises group). Studies typically reported data from one (n=46) or two
(n=21) exercise outcomes, most commonly the 6MWT (figure 3) and V′O2peak. The mean rate of attrition
from included studies was modest (table 1) but similar across intervention and control groups (11.4% versus
9.6%, respectively).
ERJ Open Res 2016; 2: 00078‐2015 | DOI: 10.1183/23120541.00078-2015 3
COPD | C.A. CAMILLO ET AL.
TABLE 1 Description of studies included in the final screening
First author [ref.] Year Completed n
(% of initial)
Respiratory rehabilitation programme Exercise test PEDro
scoreAdd-on
intervention
Components
of training
Exercise training
sessions n
Additional exercise
modalities
BENTON [9] 2013 19 (100) Single set of
resistance training
Cy, Tr 16 6MWT 4
VONBANK [10] 2012 24 (100) Strength training Cy 24 CPET 3
BERNARD [11] 1999 36 (80) Strength training Cy 36 CPET+ 5
DOURADO [12] 2009 24 (73) Strength training Tr, Cal 36 6MWT 4
PHILLIPS [13] 2006 19 (unclear) Strength training Cy, Tr, Cal, PE 13 6MWT 4
MADOR [14] 2004 24 (unclear) Strength training Cy, Tr 24 CPET, 6MWT 6
WÜRTEMBERGER [15] 2001 24 (100) Strength training Cy, PE NR CPET, 6MWT 4
ALEXANDER [16] 2008 20 (75) Strength training Cy, Tr 16 6MWT 3
HOLLAND [17] 2004 38 (100) Upper and lower
limb strength
Cy, Tr 12 6MWT 7
SUBIN [18] 2010 17 (100) Upper and lower
limb strength
Tr 20 6MWT 4
SÍVORI [19] 1998 28 (65) Upper and lower
limb strength
Cy 24 CPET, 12MWT 4
COSTI [20] 2009 46 (92) Upper and lower
limb strength
Tr, Cal, St 15 6MWT§ 8
VIVODTZEV [21]# 2006 17 (100) NMES Tr, Cal, St 16 6MWT 5
ROOYACKERS [22] 2003 24 (100) Eccentric cycling Cy, St 50 CPET, 6MWT 4
GLOECKL [23] 2012 72 (88) Whole body
vibration
Cy, Cal, St, PE,
Nut
15 6MWT§,ƒ 6
NIV
JOHNSON [24]¶ 2002 22 (79) Bi-level NIV Tr, PE 12 CPETƒ 4
TOLEDO [25] 2007 18 (100) Bi-level NIV Tr 36 CPET 3
REUVENY [26]# 2005 19 (79) Bi-level NIV Tr 16 CPET 6
COSTES [27] 2003 14 (100) Bi-level NIV Cy 24 CPET,
endurance##
4
VAN’T HUL [28]# 2006 21 (72) Inspiratory support Cy 24 ISWT,
endurance
8
HAWKINS [29] 2002 19 (66) Proportional
assisted ventilation
Cy 18 CPET,
endurance
5
BIANCHI [30] 2002 19 (58) Proportional
assisted ventilation
Cy, St, PE, Nut 18 CPET, 6MWT 5
GARROD [31] 2000 37 (82) Nocturnal NIV Cy, Tr, St, PE 16 ISWT§,ƒ 6
DUIVERMAN [32]# 2008 62 (86) Nocturnal NIV Cy, Tr, St, IMT,
PE, Nut
36, plus 69 nights
of NIV
6MWT,
endurance,
CPET
4
Oxygen
SCORSONE [33]¶ 2010 30 (100) Supplementary
oxygen
Cy 24 CPET,
enduranceƒ
5
EMTNER [34]# 2003 29 (100) Supplementary
oxygen
Cy, PE 21 CPET,
endurance
7
GARROD [35]# 2000 22 (88) Supplementary
oxygen
Cy, Tr, Cal, PE 18 ISWT 8
WADELL [36]# 2001 20 (100) Supplementary
oxygen
Tr 24 6MWT 6
DYER [37]# 2012 47 (85) Supplementary
oxygen
Tr, St, PE 14 ESWT§,ƒ 6
ROOYACKERS [38]# 1997 24 (unclear) Supplementary
oxygen
Cy, Cal, St, PE 50 CPET, 6MWT 5
BJØRGEN [39] 2009 12 (79) Supplementary
oxygen
Cy 24 CPETƒ 3
RINGBAEK [40]# 2013 38 (84) Continuous oxygen
supplement
Cy, Tr, PE 14 ESWTƒ 5
Continued
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TABLE 1 Continued
First author [ref.] Year Completed n
(% of initial)
Respiratory rehabilitation programme Exercise test PEDro
scoreAdd-on
intervention
Components
of training
Exercise training
sessions n
Heliox
JOHNSON [24]¶ 2002 21 (88) Supplementary
heliox
Tr, PE 12 CPETƒ 4
EVES [41] 2009 31 (82) Supplementary
heliox
Cy, Tr, Cal, St,
PE
16 CPET,
enduranceƒ
9
SCORSONE [33]¶ 2010 30 (100) Supplementary
heliox
Cy 24 CPET,
enduranceƒ
5
Prescription medications
PASQUA [42]# 2010 22 (100) Tiotropium Cy, Tr, Cal, IMT 20 6MWT 3
AMBROSINO [43] 2008 120 (68) Tiotropium Tr 24 6MWTƒ 8
CASABURI [44] 2005 91 (84) Tiotropium Tr 24 Endurance§ 6
CREUTZBERG [45] 2003 63 (100) Anabolic steroids Cy 40 CPET 10
FERREIRA [46]# 1998 17 (100) Anabolic steroids Cy, IMT 40 CPET, 6MWT## 7
MIKI [47]# 2012 29 (100) Ghrelin Cy, Cal, PE 45 6MWTƒ 9
BURDET [48]# 1997 16 (100) Growth hormone Aero NR 36 CPET, 6MWT## 8
MIKI [49]# 2013 20 (100) Ghrelin Cy, Cal, PE 15 CPET¶¶ 9
HORNIKX [50] 2012 49 (98) Vitamin D
supplement
Cy, Tr, St, PE 36 CPET¶¶, 6MWT 8
BLANCO [51]# 2013 41 (85) Sildenafil Cy, St 36 CPET,
enduranceƒ,
6MWT
8
SATTA [52] 1991 20 (unclear) Ubidecarenone Tr NR CPET 6
VALDERRAMAS [53] 2009 64 (94) Hypertonic saline Tr, Cal, St 24 6MWTƒ,## 8
Nutrition
LAVIOLETTE [54] 2010 20 (92) Whey protein Cy, St 24 Endurance 6
SUGAWARA [55] 2012 26 (83) MEIN (whey
protein)
Tr, Cal, IMT,
PE
NR 6MWT 8
STEINER [56] 2003 60 (70) Carbohydrates,
protein and fat
Tr, Cal, PE 14 ISWTƒ, ESWT 8
GURGUN [57]# 2013 30 (100) Carbohydrates,
protein and fat
Cy, Tr, St 16 ISWT, 6MWT 4
BROEKHUIZEN [58] 2005 80 (78) Polyunsaturated fat Cy, Tr, PE NR CPET+ 7
DEACON [59] 2008 80 (80) Creatine
monohydrate
Cy, Tr, St, PE 21 ISWTƒ, ESWT 7
FAAGER [60] 2006 23 (100) Creatine
monohydrate
Cy, Cal, St, PE 16 ESWT 5
FULD [61] 2005 25 (66) Creatine
monohydrate
Cy, Cal, St, PE 16 CPET, ISWTƒ 7
MENIER [62] 2001 60 (100) Branched-chain
amino acid
Cy, Cal, St 30 CPET 3
BORGHI-SILVA [63] 2006 16 (unclear) L-carnitine Tr, IMT 18 CPET, 6MWT§ 5
Breathing exercises
MAGADLE [64] 2007 27 (87) Inspiratory muscle
training
Cy, Tr, St 108 6MWT 7
MADOR [65] 2005 29 (76) Inspiratory muscle
training
Cy, Tr, Cal, PE 24 CPET, 6MWT 5
LARSON [66] 1999 28 (unclear) Inspiratory muscle
training
Cy 80 CPET 5
Continued
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Results from the meta-analysis, represented as mean differences weighted according to outcome, are
presented in table 3 and figure 3 (6MWT only).
Primary aim
Overall, the meta-analysis revealed few clinically relevant or statistically significant benefits of “add-on”
therapy on exercise capacity compared with pulmonary rehabilitation. Significant benefits favouring
“add-on” therapy were observed across seven different interventions (“other” additional exercise training,
NIV, tiotropium, growth hormone, vitamin D, proteins/fats and amino acids) and five different outcomes
(6MWT, V′O2peak, peak work rate, cycle endurance time and ISWT) (table 3, in bold). Most interventions
were evaluated across more than one clinical outcome; however, no single intervention category
demonstrated statistically significant benefits over multiple outcome measures (i.e. within rows, only one
significant result in table 3).
Two statistically significant negative effects were observed on exercise capacity, measured by the 6MWT.
Both were interventions within the “prescription medications” category. The mean between-group
TABLE 1 Continued
First author [ref.] Year Completed n
(% of initial)
Respiratory rehabilitation programme Exercise test PEDro
scoreAdd-on
intervention
Components
of training
Exercise training
sessions n
BERRY [67] 1996 16 (94) Inspiratory muscle
training
Tr, St 36, plus 96 IMT
sessions
CPET,
endurance,
12MWT
5
WANKE [68] 1994 42 (unclear) Inspiratory muscle
training
Cy 32, plus 56 IMT
sessions
CPET 4
WEINER [69] 1992 24 (unclear) Inspiratory muscle
training
Cy, St 72 Endurance,
12MWT§
5
DEKHUIJZEN [70]# 1991 40 (100) Inspiratory muscle
training
Cy, Tr, St 100 CPET, 12MWT 5
KUNIKOSHITA [71] 2006 15 (100) Inspiratory muscle
training
Tr, Cal 18 CPET 4
SYKES [72] 2005 37 (93) Inspiratory
muscle training
Cy, St 40 CPET, 6MWT 7
GOLDSTEIN [73] 1989 11 (100) Inspiratory
muscle training
Aero NR Exercise
training++ plus 40
IMT sessions
Endurance,
6MWT
5
COLLINS [74] 2008 33 (79) Ventilation
feedback
Cy, Tr 36 CPET,
endurance
5
VAN GESTEL [75] 2012 40 (100) Controlled
breathing
Cy, St 10 6MWT 6
Other
CARRIERI-KOHLMAN [76] 1996 51 (100) Coaching versus
monitoring
Tr 12 CPET, 6MWT 5
ZANOTTI [77] 2012 20 (100) Osteopathy Cy, St, PE 20 6MWT 9
ALEXANDER [78] 2012 27 (unclear) Harmonica playing Cy, Tr 16 6MWT 4
DE GODOY [79] 2003 30 (100) Psychotherapy Cy, Tr, Cal, St 24 6MWT 5
SHARIFABAD [80] 2010 63 (100) Written disclosure
therapy
Cy, Tr, St, PE 24 6MWT 4
NORWEG [81]¶ 2005 33 (89) Activity training/
lectures
Tr, Cal 15, plus
∼1 h·week−1
6MWT 3
DEERING [82] 2011 41 (100) Acupuncture Tr 14 ISWT 6
NIV: noninvasive ventilation; Cy: cycling; Tr: treadmill; 6MWT: 6-min walk test; CPET: cardiopulmonary exercise testing; Cal: calisthenics;
PE: psychological or educational support; NR: not reported; 12MWT: 12-min walk test; St: strengthening; NMES: neuromuscular electrical
stimulation; Nut: nutritional support; endurance: cycle endurance test; ISWT: incremental shuttle walk test; IMT: inspiratory muscle training;
ESWT: endurance shuttle walk test; Aero NR: no aerobic training details reported. #: exemplar studies of patient-centred care; ¶: study
included two appropriate interventions; +: statistically significant effect favouring intervention for peak work rate outcome; §: statistically
significant effect favouring intervention; ƒ: outcomes with adequate statistical power, according to original publication; ##: statistically
significant effect favouring control; ¶¶: statistically significant effect favouring intervention for peak oxygen uptake outcome; ++: training
duration of 4 weeks, frequency not reported. Bold indicates statistically significant effects.
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difference in 6MWT was −190.0 m (95% CI −247.34–−132.66 m; n=57) for hypertonic saline, and
−63.00 m (95% CI −91.09–−34.91 m; n=17) for anabolic steroids.
A post hoc pooled meta-analysis of the three “additional exercise training” subcategories revealed an overall
statistically significant improvement in 6MWT response (mean difference 18.41 m; 95% CI 9.18–27.63 m;
12 studies of 344 participants).
Secondary aim
18 studies used highly specific eligibility criteria, in accordance with a patient-centred care model (table 1).
When considering these data in isolation, loss of statistical significance occurred for many outcomes (table 4).
The two remaining significant findings were a positive effect of growth hormone on V′O2peak and a negative
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FIGURE 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.
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the present review.
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TABLE 2 Overview of methodological quality (PEDro score) of included studies
First author [ref.] PEDro criteria
1# 2 3 4 5 6 7 8 9 10 11 Total
Additional exercise modalities
BENTON [9] + + + + + 4
VONBANK [10] + + + 3
BERNARD [11] + + + + + + 5
DOURADO [12] + + + + + 4
PHILLIPS [13] + + + + + 4
MADOR [14] + + + + + + + 6
WÜRTEMBERGER [15] + + + + + 4
ALEXANDER [16] + + + 3
HOLLAND [17] + + + + + + + + 7
SUBIN [18] + + + + + 4
SÍVORI [19] + + + + + 4
COSTI [20] + + + + + + + + + 8
VIVODTZEV [21]¶ + + + + + + 5
ROOYACKERS [22] + + + + 4
GLOECKL [23] + + + + + + 6
NIV
JOHNSON [24]§ + + + + + 4
TOLEDO [25] + + + + 3
REUVENY [26]¶ + + + + + + 6
COSTES [27] + + + + 4
VAN ’T HUL [28]¶ + + + + + + + + 8
HAWKINS [29] + + + + + + 5
BIANCHI [30] + + + + + + 5
GARROD [31] + + + + + + + 6
DUIVERMAN [32]¶ + + + + + 4
Oxygen
SCORSONE [33]§ + + + + + 5
EMTNER [34]¶ + + + + + + + 7
GARROD [35]¶ + + + + + + + + + 8
WADELL [36]¶ + + + + + + + 6
DYER [37]¶ + + + + + + + 6
ROOYACKERS [38]¶ + + + + + + 5
BJØRGEN [39] + + + + 3
RINGBAEK [40]¶ + + + + + + 5
Heliox
JOHNSON [24]§ + + + + + 4
EVES [41] + + + + + + + + + + 9
SCORSONE [33]§ + + + + + 5
Prescription medications
PASQUA [42]¶ + + + + 3
AMBROSINO [43] + + + + + + + + + 8
CASABURI [44] + + + + + + + 6
CREUTZBERG [45] + + + + + + + + + + + 10
FERREIRA [46]¶ + + + + + + + + 7
MIKI [47]¶ + + + + + + + + + + 9
BURDET [48]¶ + + + + + + + + + 8
MIKI [49]¶ + + + + + + + + + + 9
HORNIKX [50] + + + + + + + + + 8
BLANCO [51]¶ + + + + + + + + + 8
SATTA [52] + + + + + + 6
VALDERRAMAS [53] + + + + + + + + + 8
Nutrition
LAVIOLETTE [54] + + + + + + + 6
SUGAWARA [55] + + + + + + + + + 8
STEINER [56] + + + + + + + + + 8
GURGUN [57]¶ + + + + + 4
BROEKHUIZEN [58] + + + + + + + + 7
DEACON [59] + + + + + + + + 7
Continued
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effect of anabolic steroids on 6MWT. Most findings from this analysis related to data from single and
reportedly underpowered studies.
Sensitivity analysis
The removal of quasi-randomised trials (n=2) [27, 62] did not affect any treatment effect estimates.
Findings from the principal analysis were also largely unchanged when studies deemed to be of “low”
overall quality (PEDro score ⩽5) were removed from the analysis. The only two changes of statistical
significance were the loss of benefit of nutrition supplementation (amino acids) on 6MWT due to a lack of
available data, and emergence of a large, statistically significant benefit of oxygen therapy on ESWT from
one individual study (mean difference 490.00 m; 95% CI 237.90–742.10 m; one study of 47 participants).
These data are presented in table 5.
Discussion
This review comprehensively demonstrates that, on average, “add-on” modalities rarely enhance exercise
capacity responses to conventional exercise training when applied to a general COPD population. This
“evidence of lack of effect” is different from the previous “lack of evidence of effect” observed by PUHAN
et al. [7]. Our findings demonstrate consistency with the recent British Thoracic Society guideline on
pulmonary rehabilitation, which yielded minimal supportive evidence-based recommendations regarding
the value of select adjunct therapies in pulmonary rehabilitation [84], but expand the scope of findings
across a broader range of interventions including different pharmacological interventions and additional
exercise training modalities. The latter is particularly important given the high global variation in
approaches to exercise training for patients with COPD. The lack of observed benefits in this review does
not imply that “add-on” therapies have no role for the management of patients with COPD undertaking
exercise training. Statistical significance was rarely observed in our large data synthesis; however, data from
some intervention categories (table 3) may provide insight into potentially useful strategies to guide future
TABLE 2 Continued
First author [ref.] PEDro criteria
1# 2 3 4 5 6 7 8 9 10 11 Total
FAAGER [60] + + + + + + 5
FULD [61] + + + + + + + 7
MENIER [62] + + + 3
BORGHI-SILVA [63] + + + + + 5
Breathing exercises
MAGADLE [64] + + + + + + + 7
MADOR [65] + + + + + + 5
LARSON [66] + + + + + + 5
BERRY [67] + + + + + + 5
WANKE [68] + + + + 4
WEINER [69] + + + + + 5
DEKHUIJZEN [70]¶ + + + + + + 5
KUNIKOSHITA [71] + + + + 4
SYKES [72] + + + + + + + + 7
GOLDSTEIN [73] + + + + + 5
COLLINS [74] + + + + + 5
VAN GESTEL [75] + + + + + + + 6
Other
CARRIERI-KOHLMAN [76] + + + + + + 5
ZANOTTI [77] + + + + + + + + + + 9
ALEXANDER [78] + + + + + 4
DE GODOY [79] + + + + + + 5
SHARIFABAD [80] + + + + + 4
NORWEG [81]§ + + + + 3
DEERING [82] + + + + + + + 6
1: eligibility criteria specified; 2: randomisation; 3: concealed allocation; 4: groups similar at baseline; 5: blinding of subjects; 6: blinding of
therapists; 7: blinding of assessors; 8: at least one key outcome with >85% of initially allocated subjects; 9: intention-to-treat analysis; 10:
between-group statistical comparison; 11: study provides both point measures and measures of variability for at least one key outcome; NIV:
noninvasive ventilation; +: criteria decision rule satisfied. #: item does not contribute to overall score; ¶: exemplar studies of patient-centred
care; §: study included two appropriate interventions.
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TABLE 3 Summary of treatment effect estimates, weighted according to outcome
V′O2peak
L·min−1
Peak work rate
W
Cycle endurance
min
ISWT
m
ESWT 6MWT
m
12MWT
m
Additional exercise training
LL strength 0.10 (−0.08–0.29);
N2=32i versus 28c
3.64 (−4.95–12.30);
N4=54i versus 54c
2.50 (−20.63–25.64);
N6=62i versus 68c
UL/LL strength 0.00 (−0.18–0.16);
N1=14i versus 14c
23.36 (−4.59–51.32)#;
N3=54i versus 47c
4.78 (−122.43–131.99);
N1=14i versus 14c
Other 0.10 (−0.31–0.51);
N1=12i versus 12c
−2.00 (−44.24–42.24);
N1=12i versus 12c
24.43 (0.13–48.74);
N3=57i versus 56c
NIV 0.08 (−0.08–0.24);
N3=25i versus 26c
−0.03 (−7.55–7.50);
N4=35i versus 36c
0.61 (−5.23–6.46)#;
N3=27i versus 25c
23.71 (2.65–44.77);
N2=27i versus 31c
−17.35 (−48.39–13.70);
N2=39i versus 42c
Oxygen −0.11 (−0.29–0.07);
N3=36i versus 32c
−1.38 (−5.47–2.72);
N3=36i versus 32c
4.70 (−1.96–11.36);
N1=14i versus 15c
233.38 (−245.24–712.0) m#;
N2=40i versus 45c
−37.0 (−98.61–24.61);
N1=12i versus 12c
Heliox 0.02 (−0.04–0.08);
N2=26i versus 20c
4.61 (−0.50–9.72);
N2=26i versus 20c
5.20 (−0.17–10.57);
N1=16i versus 15c
Prescription medications
Tiotropium 5.35 (0.89–9.81);
N1=47i versus 44c
7.06 (−15.13–29.26);
N2=68i versus 74c
Anabolic steroids 0.10 (−0.02–0.23);
N1=33i versus 30c
4.00 (−5.28–13.28);
N1=33i versus 30c
−63.0 (−91.09–−34.91);
N1=10i versus 7c
Growth hormone 0.05 (0.01–0.09);
N2=18i versus 18c
−11.00 (−26.48–4.48);
N1=8i versus 8c
−26.21 (−148.92–96.50)#;
N2=22i versus 23c
Vitamin D 0.64 (0.07–1.22);
N1=25i versus 24c
7.00 (−0.28–14.28);
N1=25i versus 24c
29.0 (−7.62–65.62);
N1=25i versus 24c
Hypertonic saline −190.0
(−247.34–−132.66);
N1=30i versus 27c
Nutritional supplementation
Proteins/fats −0.03 (−0.12–0.06);
N1=38i versus 42c
9.00 (4.32–13.68);
N1=38i versus 42c
2.86 (−2.00–7.72);
N1=10i versus 10c
−19.48 (−42.23–3.27);
N2=40i versus 50c
−0.24 (−1.65–1.17) min;
N1=15i versus 15c
8.02 (−31.21–47.26);
N2=31i versus 25c
Creatine 0.14 (−0.02–0.29);
N1=14i versus 11c
4.29 (−9.53–18.11);
N1=14i versus 11c
−3.62 (−31.75–24.52);
N2=52i versus 53c
−0.11 (−0.46–0.24) units¶;
N3=65i versus 63c
Amino acids −0.90 (−14.55–12.75);
N1=30i versus 30c
53.00 (24.09–81.91);
N1=8i versus 8c
Breathing exercises
Inspiratory muscle training 0.03
(−0.26–0.31) units¶;
N6=97i versus 95c
−0.07 (−10.56–10.43);
N4=70i versus 69c
12.72 (−16.21–42.26);
N4=55i versus 49c
211.45
(−56.66–479.56)#;
N3=39i versus 41c
Breathing retraining 0.20 (−1.58–1.98);
N1=17i versus 16c
8.50 (−4.38–21.38);
N1=17i versus 16c
−12.58 (−35.93–10.77);
N1=20i versus 20c
Other −0.28 (−0.83–0.27);
N1=24i versus 27c
3.20 (−24.06–30.46);
N1=16i versus 25c
10.26 (−21.85–42.38);
N6=78i versus 183c
Data are presented as mean difference (95% CI), where the mean difference is the change from baseline and a positive effect estimate favours intervention (“add-on” therapies). Data
from individual studies may appear more than once across different outcomes (columns). V′O2peak: peak oxygen uptake; ISWT: incremental shuttle walk test; ESWT: endurance shuttle
walk test; 6MWT: 6-min walk test; 12MWT: 12-min walk test; LL: lower limb; UL: upper limb; NIV: noninvasive ventilation; Nx: number of participants (x is number of studies);
i: intervention group; c: control group. #: random effects model; ¶: standardised mean difference. Bold indicates statistically significant treatment effect.
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research. For example, the magnitude and direction of effect estimates (although nonsignificant) were
consistent across all except one study within the “additional exercise training modalities” category for
V′O2peak, peak work rate, 6MWT and 12MWT. The magnitude of estimated mean improvement in 6MWT
following both “upper and lower limb strength” and “other” training subcategories was also close to the
threshold of the minimally important difference (MID) for this outcome [85, 86]. Further research may
therefore be warranted to investigate the potential for additional exercise training modalities to enhance
exercise training effects, in more select patient subgroups. Our post hoc pooled analysis of the three
Subgroups and studies
Additional exercise training
Upper and lower limb training
Lower limb strength training
Inspiratory muscle training
DOURADO [12]
PHILLIPS [13]
BENTON [9]
MADOR [14]
WÜRTEMBERGER [15]
ALEXANDER [16]
Subtotal (95% CI)
SYKES [72]
VAN GESTEL [75]
MAGADLE [64]
GOLDSTEIN [73]
MADOR [65]
Subtotal (95% CI)
CARRIERI-KOHLMAN [76]
Subtotal (95% CI)
Subtotal (95% CI)
Other training
Subtotal (95% CI)
NIV
Oxygen supplementation
COSTI [20]
SUBIN [18]
HOLLAND [17]
ZANOTTI [77]
ALEXANDER [78]
DE GODOY [79]
NORWEG [81]
NORWEG [81]
VIVODTZEV [21]
GLOECKL [23]
ROOYACKERS [22]
Subtotal (95% CI)
PASQUA [42]
Subtotal (95% CI)
FERREIRA [46]
HORNIKX [50]
Breathing exercises
VALDERRAMAS [53]
Other
MIKI [47]
ROOYACKERS [38]
Subtotal (95% CI)
Prescription medications
Nutritional supplementation
DUIVERMAN [32]
AMBROSINO [43]
BURDET [48]
BIANCHI [30]
SUGAWARA [55]
BORGHI-SILVA [63]
GURGUN [57]
Subtotal (95% CI)
Breathing retraining
Intervention Control
11
10
Participants n
10
11
10
10
62
20
20
14
6
15
55
24
78
57
54
23
9
22
10
9
14
11
10
9
36
12
68
11
22
10
25
30
14
12
39
30
57
8
9
16
8
15
39
Weight 
%
21.1
16.3
17.2
5.6
33.8
6.0
100.0
38.3
NA
18.6
28.1
15.0
100.0
25.2
100.0
–200
Favours
control
Favours 
experimental
–100 0 100 200
100.0
100.0
34.3
38.6
27.1
17.1
4.6
24.5
14.5
14.2
6.7
89.1
4.2
100.0
8.9
100.0
NA
NA
NA
56.3
NA
100.0
30.0
91.1
43.7
70.0
3.7
64.8
31.5
100.0
(95% CI)
Mean difference
17.00 (–33.35–67.35)
6.10 (–51.22–63.42)
3.50 (–52.27–59.27)
–4.60 (–102.05–92.85)
–5.40 (–45.21–34.41)
–10.05 (–104.79–84.69)
2.50 (–20.63–25.64)
35.40 (–12.33–83.13)
–12.58 (–35.93–10.77)
17.90 (–50.58–86.38)
–4.00 (–59.74–51.74)
–20.20 (–96.36–55.96)
12.72 (–16.81–42.26)
–46.02 (–110.02–17.98)
10.26 (–21.85–42.38)
24.43 (0.13–48.74)
23.36 (–4.59–51.32)#
50.20 (28.87–71.53)
10.40 (–3.68–24.48)
7.90 (–24.61–40.41)
64.80 (–12.94–142.54)
39.24 (–110.32–188.80)
35.30 (–29.63–100.23)
19.63 (–64.80–104.06)
–17.52 (–102.70–67.66)
39.00 (–54.57–132.57)
26.70 (0.94–52.46)
–47.00 (–165.60–71.60)
7.06 (–15.13–29.26)
4.66 (–69.63–78.95)
–26.21 (–148.92–96.50)#
–63.00 (–91.09– –34.91)
29.00 (–7.62–65.62)
–190.00 (–247.34– –132.66)
29.00 (–10.69–68.69)
–37.00 (–98.61–24.61)
–17.35 (–48.39–13.70)
15.00 (–41.69–71.69)
7.30 (–15.96–30.56)
–97.21 (–193.28– –1.14)
–31.20 (–68.30–5.90)
82.70 (–38.59–203.99)
53.00 (24.09–81.91)
–0.70 (–42.16–40.76)
37.17 (13.89–60.44)
13
9
9
13
14
10
68
17
20
13
5
14
49
27
83
56
47
23
8
16
10
18
16
6
6
8
36
12
74
11
23
7
24
27
15
12
42
32
63
8
10
10
8
15
33
Intervention type
Strength training
Strength training
Single set of resistance training
Strength training
Strength training
Strength training
Inspiratory muscle training
Controlled breathing
Inspiratory muscle training
Inspiratory muscle training
Inspiratory muscle training
Coaching versus monitoring
Upper and lower limb strength
Upper and lower limb strength
Upper and lower limb strength
Osteopathy
Harmonica playing
Psychotherapy
Activity training
Lectures
Whole body vibration
NMES
Eccentric cycling
Tiotropium
Anabolic steroids
Vitamin D supplementation
Hypertonic saline
Growth hormone
Supplemental oxygen
Nocturnal NIV
Tiotropium
Growth hormone
Proportional assist ventilation
MEIN (whey protein)
L-carnitine 
Carbohydrates, protein and fat
outcomes
Other reported 
CPET
CPET
CPET
Endurance
CPET
CPET
CPET
CPET
CPET¶
CPET
Endurance, CPET
CPET
CPET
CPET
ISWT
FIGURE 3 Forest plot of the effect of “add-on” therapies on 6-min walking distance change (in metres). Effect estimates (mean differences) without
coloured shading denote unweighted analyses of data from single studies within intervention groups or subgroups. CPET: cardiopulmonary cycle
exercise test; NMES: neuromuscular electrical stimulation; NIV: noninvasive ventilation; NA: not available; ISWT: incremental shuttle walk test.
#: random effects model used for meta-analysis; ¶: statistically significant positive effect reported.
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TABLE 4 Summary of standardised effect estimates for studies defined as “exemplar” models of patient-centred care
V′O2peak
L·min−1
Peak work rate
W
Cycle endurance
min
ISWT
m
ESWT 6MWT
m
12MWT
m
Additional exercise training
LL strength
UL/LL strength
Other 39.00 (−54.57–132.57);
N1=9i versus 8c
NIV 0.15 (−0.29–0.59) units¶;
N2=39i versus 42c
8.00 (−5.53–21.53);
N1=9i versus 10c
3.50 (−1.38–8.38);
N1=10i versus 11c
17.00 (−5.47–39.47);
N1=10i versus 11c
15.00 (−41.69–71.69);
N1=30i versus 32c
Oxygen −4.52 (−17.07–8.03);
N2=26i versus 27c
4.70 (−1.96–11.36);
N1=14i versus 15c
233.38 (−245.24–712.0) m#;
N2=40i versus 45c
−37.0 (−98.61–24.61);
N1=12i versus 12c
Heliox
Prescription medications
Tiotropium 4.66 (−69.63–78.95);
N1=11i versus 11c
Anabolic steroids −0.59 (−1.58–0.40) units¶;
N1=10i versus 7c
−63.0 (−91.09–−34.91);
N1=10i versus 7c
Growth hormone 0.05 (0.01–0.09);
N2=18i versus 18c
−26.21 (−148.92–96.50)#;
N2=22i versus 23c
Vitamin D
Hypertonic saline
Nutritional supplementation
Proteins/fats −26.00 (−72.28–20.28);
N1=15i versus 15c
−0.12 (−0.84–0.6) units¶;
N1=15i versus 15c
−0.70 (−42.16–40.76);
N1=15i versus 15c
Creatine
Amino acids
Breathing exercises
Inspiratory muscle training −0.06 (−0.19–0.07);
N1=20i versus 20c
−7.00 (−32.90–18.90);
N1=20i versus 20c
69.00 (−154.89–292.89);
N1=20i versus 20c
Breathing retraining
Other
Data are presented as mean difference (95% CI), where the mean difference is the change from baseline and a positive effect estimate favours intervention (“add-on” therapies). Data
from individual studies may appear more than once across different outcomes (columns). V′O2peak: peak oxygen uptake; ISWT: incremental shuttle walk test; ESWT: endurance shuttle
walk test; 6MWT: 6-min walk test; 12MWT: 12-min walk test; LL: lower limb; UL: upper limb; NIV: noninvasive ventilation; Nx: number of participants (x is number of studies);
i: intervention group; c: control group. #: random effects model; ¶: standardised mean difference. Bold indicates statistically significant treatment effect.
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TABLE 5 Sensitivity analysis: summary of treatment effect estimates, weighted according to outcome, including studies with PEDro scores >5 only
V′O2peak
L·min−1
Peak work rate
W
Cycle endurance
min
ISWT
m
ESWT 6MWT
m
12MWT
m
Additional exercise training
LL strength −0.10 (−0.43–0.23);
N1=11i versus 13c
9.00 (−14.60–32.60);
N1=11i versus 13c
−4.60 (−102.05–92.85);
N1=11i versus 13c
UL/LL strength 30.90 (−10.39–72.20)#;
N2=45i versus 39c
Other 26.70 (0.94–52.46);
N1=36i versus 36c
NIV 0.08 (−0.15–0.32);
N1=9i versus 10c
8.00 (−5.53–21.53);
N1=9i versus 10c
3.50 (−1.38–8.38);
N1=10i versus 11c
23.71 (2.65–44.77);
N2=27i versus 31c
Oxygen −0.04 (−0.26–0.18);
N1=14i versus 15c
3.00 (−16.32–22.32);
N1=14i versus 15c
4.70 (−1.96–11.36);
N1=14i versus 15c
490.00 (237.90–742.10) m;
N1=24i versus 23c
Heliox 0.02 (−0.04–0.08);
N2=16i versus 15c
4.00 (−4.15–12.15);
N1=16i versus 15c
5.20 (−0.17–10.57);
N1=16i versus 15c
Prescription medications
Tiotropium 5.35 (0.89–9.81);
N1=47i versus 44c
7.30 (−15.96–30.56);
N1=57i versus 63c
Anabolic steroids 0.10 (−0.02–0.23);
N1=33i versus 30c
4.00 (−5.28–13.28);
N1=33i versus 30c
−63.0 (−91.09–−34.91);
N1=10i versus 7c
Growth hormone 0.05 (0.01–0.09);
N2=18i versus 18c
−11.00 (−26.48–4.48);
N1=8i versus 8c
−26.21 (−148.92–96.50)#;
N2=22i versus 23c
Vitamin D 0.64 (0.07–1.22);
N1=25i versus 24c
7.00 (−0.28–14.28);
N1=25i versus 24c
29.0 (−7.62–65.62);
N1=25i versus 24c
Hypertonic saline −190.0 (−247.34–−132.66);
N1=30i versus 27c
Nutritional supplementation
Proteins/fats −0.03 (−0.12–0.06);
N1=38i versus 42c
9.00 (4.32–13.68);
N1=38i versus 42c
2.86 (−2.00–7.72);
N1=10i versus 10c
−17.40 (−43.52–8.72);
N1=25i versus 35c
82.70 (−38.59–203.99);
N1=16i versus 10c
Creatine 0.14 (−0.02–0.29);
N1=14i versus 11c
4.29 (−9.53–18.11);
N1=14i versus 11c
−3.62 (−31.75–24.52);
N2=52i versus 53c
−0.67 (−2.96–1.63) min;
N2=52i versus 53c
Amino acids
Breathing exercises
Inspiratory muscle training 0.48 (−0.17–1.14) units¶;
N1=20i versus 17c
29.68 (−9.48–68.84);
N2=34i versus 30c
Breathing retraining −12.58 (−35.93–10.77);
N1=20i versus 20c
Other 3.20 (−24.06–30.46);
N1=16i versus 25c
64.80 (−12.94–142.54);
N1=10i versus 10c
Data are presented as mean difference (95% CI), where the mean difference is the change from baseline and a positive effect estimate favours intervention (“add-on” therapies).
Data from individual studies may appear more than once across different outcomes (columns). V′O2peak: peak oxygen uptake; ISWT: incremental shuttle walk test; ESWT: endurance
shuttle walk test; 6MWT: 6-min walk test; 12MWT: 12-min walk test; LL: lower limb; UL: upper limb; NIV: noninvasive ventilation; Nx: number of participants (x is number of studies);
i: intervention group; c: control group. #: random effects model; ¶: standardised mean difference. Bold indicates statistically significant treatment effect.
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“additional exercise training” subcategories revealed that the upper limit of the confidence interval
(27.63 m) was within the range of the MID for the 6MWT. Importantly, the study findings do not detract
from the potential clinical benefits of “add-on” therapies on outcomes such as symptoms or quality of life.
While improvement in such outcomes is unlikely to be mediated exclusively by extrapulmonary (e.g.
musculoskeletal) physiological adaptations in response to exercise training, associated alterations in factors
such as breathing pattern or subjective control of dyspnoea remain clinically important. Such benefits have
been clearly documented in the pulmonary rehabilitation literature [2].
The review also provides evidence from individual studies of negative effects of hypertonic saline and
anabolic steroids on 6MWT response, with data from two studies highlighting reductions greatly exceeding
the MID [46, 53]. Importantly, supplementation of anabolic steroids is primarily used to enhance muscle
strength [87]. While a significant decrease in muscle strength or function would not be an expected
consequence of supplementation, it should also not be assumed that exercise capacity would be guaranteed
to improve as a result of a pharmacological intervention targeting the cellular genesis of hypertrophic muscle
responses. Unless new data emerge, demonstrating opposing findings, the continued use of these
interventions in conjunction with standard exercise training in pulmonary rehabilitation appears inadvisable.
The general lack of observed benefit across the breadth of interventions and outcomes could have been
affected by three factors. First, as pulmonary rehabilitation comprising exercise training is already a highly
effective treatment for patients with COPD [1], further improvements in exercise capacity via “add-on”
modalities may be challenging to obtain. This is particularly relevant when one considers that pulmonary
rehabilitation targets extrapulmonary features of COPD, particularly muscle composition and function,
which may have realistic ceilings in terms of the magnitude of expected improvement within a short
time-frame. This raises subsequent issues regarding attainable statistical power and sample size estimations
for future clinical trials of “add-on” therapies to exercise training in COPD. In such studies, conventional
MID thresholds of improvement may not be the most appropriate measure of clinical importance if the
underlying exercise training co-intervention is expected to be highly effective for the same outcome.
Smaller subsequent levels of improvement (e.g. +15 m on top of +30 m 6MWT change) could, for
example, be clinically meaningful. Identifying the importance of such additional effects for clinicians and
healthcare providers could perhaps be facilitated via use of more intuitive research metrics than those
commonly seen in the relevant literature. For example, data regarding the “number needed to treat” (the
number of patients that need to be treated to have a meaningful impact on one person) were not available
in any study included in the review, yet this offers a simple estimate of clinical value in consideration of
broader issues such as cost-effectiveness.
Secondly, although the effects of “add-on” therapies on exercise capacity were reported for all
interventions included in the review, not all interventions primarily target direct improvements in exercise
capacity (e.g. psychotherapy or self-management). Interventions such as NIV, for example, aim to
ameliorate negative physiological responses to exercise training (such as ventilation limitation) and reduce
symptom burden. These indirect influences on exercise training responses may not be fully captured
within measures of exercise performance alone. Related to this, the fidelity of interventions must be
carefully considered, to ensure they are applied appropriately (i.e. to achieve their stated purpose) and
deemed adequately acceptable to patients (i.e. to ensure adherence). This may have limited the
effectiveness of some interventions in this review, such as NIV applied at very low intensities during
training. It would be interesting to speculate whether improvement of symptoms during exercise would
improve treatment adherence; however, this was not explicitly examined in the present review. These issues
highlight the importance of carefully selected outcome reporting in future investigations, and the need for
consensus among researchers, clinicians and policy makers to identify the outcomes considered most
important to inform clinical practice.
Thirdly, pulmonary rehabilitation studies rarely account for significant disease heterogeneity in COPD. The
“one size fits all” model of care applied in most clinical trials seems to derive favourable, clinically
important benefits to COPD patients on average; however, further improvements with “add-on” therapies
may only be possible in specific patient subgroups. Intuition might suggest the use of highly specific
eligibility criteria well suited to “add-on” interventions might be associated with positive results. This was
not, however, supported by the findings of our secondary analysis. Interpretation of these exemplar studies
was limited by small sample size and low number of studies adopting this approach. This, in itself, is a
highly important outcome of the present review that should inform future research. While such
patient-centred studies may not yield positive results on exercise capacity, they are likely to confer more
accurate information about the true clinical utility of interventions, as they represent the best available
estimate of effectiveness in well-defined patient subgroups most likely to derive benefit. Further studies
should also strive to achieve adequate statistical power for key outcomes, as small sample sizes and resultant
under-powering was a likely contributor to the lack of significant findings observed in this review.
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Studies in specific COPD clinical phenotypes are more difficult to conduct, as recruitment is typically
slower, with a potential impact upon statistical power. Such studies may confer less external validity than
broader studies, but the potential for clinically applicable findings is increased. The development of strong
multicentre, international collaborations appears essential in order to conduct high-quality large
randomised controlled trials to advance future clinical practice. The diverse organisation of pulmonary
rehabilitation programmes across the world [88] can impede such studies; however, standardisation of
pulmonary rehabilitation research outcomes, similar to the widespread use of the forced expiratory volume
in pharmacological studies, could help overcome this issue. Adoption of “mandatory” outcomes for
reporting exercise performance could aid this process, such as the extensive use and importance of the
6MWT documented in recent pulmonary rehabilitation guidelines [85, 89].
Limitations
While pulmonary rehabilitation benefits are well documented on outcomes such as exercise capacity,
quality of life and healthcare utilisation [2, 3], the scope of the present review was restricted to outcomes of
exercise capacity, admittedly an essential outcome in pulmonary rehabilitation. This was necessary due to
the large number of anticipated studies included in the review. The findings therefore relate exclusively to
this essential mechanism underpinning exercise training benefits. Potential effects of “add-on” therapies on
other important outcomes, such as symptoms or quality of life, should not be extrapolated from our data.
We also included end-point data where changes from baseline data were unavailable. This significantly
increased the volume of data and opportunity for meta-analysis to improve findings from the earlier
review in this area [7]. A known negative effect of this method, however, is relative overweighting to data
from studies contributing change data compared with those contributing end-point data. This is due to
the typically narrower confidence intervals around change data compared with end-point data. The
consistency of results across clinical trials (figure 3), however, suggests this did not adversely affect the
review findings.
The heterogeneous array of interventions and limited opportunity for meta-analysis for some outcomes
meant that interpretation of some findings and identification of clinical implications was difficult. Some
interventions within the same group have similar goals but work through different mechanisms
(e.g. neuromuscular electrical stimulation, vibration training and eccentric training to improve muscle
function within the “additional training modalities” group). Significant statistical heterogeneity was
observed within some outcomes (tables 3 and 4). Despite attempts to maximise opportunities for data
pooling, the resultant number of included participants in the meta-analyses was quite low. This was
particularly evident in the analysis of carefully selected COPD subgroups (i.e. patient-centred studies) and
reinforced the difficulty of drawing clinically meaningful conclusions from the large body of literature in
this field. Given the observed rate of attrition across studies (table 1), it also seems important that future
studies report findings with strict adherence to the principle of intention-to-treat, in order to clarify the
true value of treatments applied in the context of “real life” settings. These limitations offer strong support
for change in the approach taken towards future investigations in this area. Exercise training represents a
complex intervention and standardisation of programme length, intensity and basic outcome reporting
would greatly assist the interpretation of future analyses.
Conclusion
Results from our large data synthesis of a diverse array of “add-on” physical, pharmacological, nutritional
and behavioural interventions demonstrate minimal clinically important improvements in exercise capacity
above those expected from conventional exercise training in pulmonary rehabilitation. This provides a
compelling argument discouraging continued attempts to investigate the effectiveness of different “add-on”
modalities on exercise capacity using methodologies similar to those included in this review. This does
not, however, mean it is unimportant to conduct further studies of “add-on” therapies in this patient
group, particularly evaluation of their effect on other outcomes from those covered in this review.
Identification of the true value of such therapies may, however, not emerge until studies are carefully
designed and implemented in highly selective patient groups using the most appropriate outcomes.
As many pulmonary rehabilitation benefits are driven by physiological change in the peripheral skeletal
muscles in response to exercise training, it seems sensible for future clinical trials of interventions in this
area to be based upon a strong physiological foundation for specific muscular targets (whether at cellular
tissue sites or a physical function level) in select clinical COPD phenotypes. Such interventions should be
associated with markers of improvement in relevant outcomes such as exercise capacity and muscle force.
Definitive answers regarding the future of pulmonary rehabilitation are therefore only likely to emerge from
carefully designed investigations of specific interventions in select patients in larger multicentre studies.
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